There has been great development of CAR-T cell therapies in treating both hematological neoplasms and other neoplasms in recent years, and these therapies show better efficacy in CD19-positive lymphomas than in CD19-negative lymphomas, with a promising ORR of 52~83% (6–8). Here, CD19 is linked to neoplasm.